$3.86
ADC Therapeutics is a biotechnology business based in the US. ADC Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. ADC Therapeutics employs 273 staff and has a trailing 12-month revenue of around $68.6 million.
Our top picks for where to buy ADC Therapeutics stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- No-cost financial planning and automated investing
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
How to buy ADC Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ADCT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy ADC Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
ADC Therapeutics stock price (NYSE: ADCT)
Use our graph to track the performance of ADCT stocks over time.ADC Therapeutics shares at a glance
Latest market close | $3.86 |
---|---|
52-week range | $0.36 - $6.04 |
50-day moving average | $3.49 |
200-day moving average | $2.91 |
Wall St. target price | $10.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-2.77 |
Is it a good time to buy ADC Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ADC Therapeutics price performance over time
Historical closes compared with the close of $3.86 from 2024-07-23
1 week (2024-07-17) | 2.12% |
---|---|
1 month (2024-06-24) | 43.49% |
3 months (2024-04-24) | -19.25% |
6 months (2024-01-24) | 83.81% |
1 year (2023-07-24) | 194.66% |
---|---|
2 years (2022-07-22) | -47.55% |
3 years (2021-07-23) | 21.55 |
5 years (2019-07-20) | N/A |
ADC Therapeutics financials
Revenue TTM | $68.6 million |
---|---|
Gross profit TTM | $35.1 million |
Return on assets TTM | -24.08% |
Return on equity TTM | -705.53% |
Profit margin | 0% |
Book value | $-2.35 |
Market Capitalization | $331 million |
TTM: trailing 12 months
ADC Therapeutics share dividends
We're not expecting ADC Therapeutics to pay a dividend over the next 12 months.
ADC Therapeutics share price volatility
Over the last 12 months, ADC Therapeutics's shares have ranged in value from as little as $0.3599 up to $6.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ADC Therapeutics's is 1.598. This would suggest that ADC Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ADC Therapeutics overview
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U. S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets.
Frequently asked questions
nullWhat percentage of ADC Therapeutics is owned by insiders or institutions?
Currently 21.058% of ADC Therapeutics shares are held by insiders and 41.877% by institutions. How many people work for ADC Therapeutics?
Latest data suggests 273 work at ADC Therapeutics. When does the fiscal year end for ADC Therapeutics?
ADC Therapeutics's fiscal year ends in December. Where is ADC Therapeutics based?
ADC Therapeutics's address is: Biopôle, Epalinges, Switzerland, 1066 What is ADC Therapeutics's ISIN number?
ADC Therapeutics's international securities identification number is: CH0499880968
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Frec review 2024: Low-cost direct indexing and individual stock trading
A deep dive into the highlights and limitations of Frec.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question